The openFDA Drugs@FDA record for NDA 218784 covers one of the more scientifically notable oncology approvals of the current cycle: Servier's VORANIGO, brand name for vorasidenib, an oral tablet supplied in 10 mg and 40 mg strengths. The record now shows an approved labeling supplement (SUPPL-4, class LABELING, status AP, standard review). The headline event, though, is upstream in the same history: the original submission (ORIG-1) was approved on 6 August 2024, classified Type 1 — New Molecular Entity and granted priority review. Those two regulatory flags — new molecular entity, priority review — mark vorasidenib as a genuinely new, genuinely significant drug rather than a line extension.
What makes it significant is the target. Vorasidenib inhibits mutant forms of the isocitrate dehydrogenase enzymes IDH1 and IDH2. Mutations in these enzymes are a defining molecular feature of a subset of diffuse gliomas — primary brain tumors — and they had long been understood as drivers of the disease without a drug that directly addressed them in this setting. Vorasidenib was engineered as a brain-penetrant IDH inhibitor, meaning it is designed to cross into the central nervous system and act on the tumor where it lives. For IDH-mutant grade 2 glioma — a cancer that historically forced clinicians to weigh the harsh toll of radiation and chemotherapy against watchful waiting — an oral targeted therapy represented a different kind of option entirely.
Why this approval re-rated a therapeutic area
Grade 2 gliomas are often diagnosed in younger adults and can smolder for years before progressing, which makes the treatment calculus agonizing: intervene early with toxic therapy, or wait and risk progression. A well-tolerated oral drug that can delay the need for radiation and chemotherapy changes that calculus directly. That is why vorasidenib's arrival drew attention well beyond the usual oncology audience, and why the FDA's priority-review designation — reserved for drugs that would be a significant improvement in treating a serious condition — fits the record. The drug created, in effect, a new front-line targeted option in a tumor type that had been starved of them.
The commercial frame follows from the science. A first-in-class, brain-penetrant targeted therapy in a defined molecular subset is a defensible asset: the patient population is identifiable by IDH-mutation testing, the mechanism is differentiated, and there was no direct prior competitor in the indication. For Servier — a company that has built deliberately in oncology, including in the IDH-mutation space — vorasidenib anchors a franchise rather than merely adding a product. The labeling supplement now on the record is part of tending that franchise: keeping the prescribing information current as the evidence base grows.
The trials are still running
And the evidence base is, demonstrably, still growing. ClinicalTrials.gov shows active late-stage programs around vorasidenib beyond the registrational study. One Phase 3 study (NCT06780930) is evaluating vorasidenib in Asian participants with residual or recurrent grade 2 glioma carrying an IDH1 or IDH2 mutation, listed as active and not recruiting. A separate study (NCT06478212) is examining vorasidenib in combination with temozolomide — the standard alkylating chemotherapy — in IDH-mutant glioma, also active and not recruiting. The combination question is strategically important: whether a targeted IDH inhibitor pairs with established chemotherapy could shape how the drug is used and how broadly. These ongoing trials are exactly the pipeline of data that drives future labeling supplements, indication expansions, and the geographic broadening of an oncology franchise.
Reading the supplement against the arc
So how should a reader weigh SUPPL-4 itself? With the same discipline applied to any regulatory event: it is a labeling supplement, not a new indication or a new molecular entity, so the openFDA record does not show the addressable population changing on this filing. The record also shows it is not the first label update — SUPPL-2 was approved in April 2025 — meaning Servier has a pattern of keeping the label current. A labeling supplement updates prescribing information; its specific changed text is not published in the public summary, which is normal.
The value of the record is in the whole arc it traces, not the single line. A priority-reviewed first-in-class new molecular entity cleared in August 2024; a cadence of approved labeling supplements through 2026; and a live set of Phase 3 trials feeding the next wave of data. Put together, that is the profile of an oncology asset in active expansion — launched, defended, and still being studied to widen its use. The single supplement is a maintenance event; the trajectory it sits within is a growth story. For a desk that treats therapeutics as an asset class, the openFDA record for NDA 218784, read alongside the open ClinicalTrials.gov programs, is the clearest public ledger of where that story stands.
Why the combination and geographic trials are the real catalysts
It is worth being explicit about why the two ongoing Phase 3 studies matter more to the asset's long-term value than this individual labeling supplement does. The combination trial pairing vorasidenib with temozolomide (NCT06478212) asks whether a targeted IDH inhibitor can be layered on top of standard alkylating chemotherapy — and a positive answer would not just add a use, it could reposition the drug within the treatment sequence and broaden the population that benefits. The Asian-population study (NCT06780930) addresses a different lever: geographic expansion. Oncology franchises grow by both indication and geography, and a dedicated regional trial is how a sponsor builds the evidence and regulatory basis to extend a drug's reach beyond its initial markets. Both are listed as active and not recruiting, meaning enrollment is complete and the studies are progressing toward readouts.
Those readouts, when they come, are the genuine catalysts — the events that could drive new efficacy supplements, new indications, and a materially larger addressable population. The labeling supplement on today's record is maintenance; the trials are the engine of future value. Holding those two facts together is the whole point of reading a regulatory record with discipline: the quiet filing keeps the existing approval current, while the pipeline behind it determines how big the franchise ultimately becomes. For vorasidenib, a first-in-class brain-penetrant IDH inhibitor in a tumor type long starved of targeted options, the combination of an active Drugs@FDA record and live late-stage trials is the signature of an asset still early in its arc.